MedTrace Logo

Improving Resilience With Whole Grain Wheat

NCT02385149 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-11-20

No results posted yet for this study

Summary

This study investigates the health benefits of whole grain wheat on cardiovascular/ cardio-metabolic health, including glucose metabolism, by means of applying a mixed meal challenge. This study also investigates the health benefits of whole grain wheat (WGW) on liver- and adipose tissue health and evaluates the potential of do-it-yourself (DIY) devices in quantifying health effects in a nutritional intervention study.

Conditions

  • Healthy
  • Metabolism

Interventions

OTHER

whole grain wheat

A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).

OTHER

refined wheat

A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).

Sponsors & Collaborators

  • TNO

    collaborator OTHER

  • Cereal Partners Worldwide

    collaborator INDUSTRY

  • Nederlands Bakkerij Centrum

    collaborator OTHER

  • Goodmills

    collaborator UNKNOWN

  • University Medical Center Groningen

    collaborator OTHER

  • Wageningen University

    lead OTHER

Principal Investigators

  • Lydia Afman, PhD · Wageningen University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02385149 on ClinicalTrials.gov